• Alias: CCI-779
    • An ester analog of rapamycin that binds to and inhibits mTOR, resulting in a reduced expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle
    • FDA approved for renal cell carcinoma
    • Recommended dose: 25 mg infusion over 30 to 60 minutes once a week. Pretreatment with antihistamine recommended
    • Half-life: 17.3 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Rash, asthenia, mucositis, nausea, edema, anorexia, anemia, hyperglycemia, hyperlipidemia
    • Clinical pearls: For management of fatigue: Encourage exercise and good sleep hygiene, initiate rect sunlight, use moisturizers after bathing, use mild soap for bathing, antihistamines for itching, be aware of possibility of lung toxicity, monitor fasting triglycerides and cholesterol. Levels may increase while on treatment.
    Other topics in Targeted and Immunotherapy Agents